Dominique Schols
Rega Institute for Medical Research
Katholieke Universiteit Leuven
Belgium
Name/email consistency: high
- HIV co-receptors as targets for antiviral therapy. Schols, D. Curr. Top. Med. Chem (2004)
- T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. Schols, D., Esté, J.A., Cabrera, C., De Clercq, E. J. Virol. (1998)
- The simian immunodeficiency virus mnd(GB-1) strain uses CXCR4, not CCR5, as coreceptor for entry in human cells. Schols, D., De Clercq, E. J. Gen. Virol. (1998)
- CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Schols, D., Proost, P., Struyf, S., Wuyts, A., De Meester, I., Scharpé, S., Van Damme, J., De Clercq, E. Antiviral Res. (1998)
- RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). Schols, D., Proost, P., Van Damme, J., De Clercq, E. J. Virol. (1997)
- Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Schols, D., Struyf, S., Van Damme, J., Esté, J.A., Henson, G., De Clercq, E. J. Exp. Med. (1997)